| 31.75 1.42 (4.68%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.75 |
1-year : | 46.43 |
| Resists | First : | 34.04 |
Second : | 39.75 |
| Pivot price | 31.34  |
|||
| Supports | First : | 30.9 |
Second : | 28.95 |
| MAs | MA(5) : | 30.71 |
MA(20) : | 31.65 |
| MA(100) : | 25.15 |
MA(250) : | 19.35 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 44.6 |
D(3) : | 36.4 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 34.04 | Low : | 9.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VRDN ] has closed below upper band by 35.8%. Bollinger Bands are 29.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.88 - 32.05 | 32.05 - 32.22 |
| Low: | 30.13 - 30.36 | 30.36 - 30.58 |
| Close: | 31.41 - 31.75 | 31.75 - 32.06 |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Fri, 09 Jan 2026
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026 - BioSpace
Thu, 08 Jan 2026
VRDN: Truist Securities Lowers Price Target but Maintains Buy Ra - GuruFocus
Wed, 07 Jan 2026
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Wed, 07 Jan 2026
VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price Target | VRDN Stock News - GuruFocus
Tue, 06 Jan 2026
Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Exploring a Potential 36.59% Upside in the Biotech Arena - DirectorsTalk Interviews
Tue, 06 Jan 2026
Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 9.003e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 9,470 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.2416e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -56.8 % |
| Return on Assets (ttm) | -30.1 % |
| Return on Equity (ttm) | -49.9 % |
| Qtrly Rev. Growth | 81 % |
| Gross Profit (p.s.) | 1052.85 |
| Sales Per Share | 7.77912e+007 |
| EBITDA (p.s.) | -2.71857e+008 |
| Qtrly Earnings Growth | -3.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -326 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 7.56 |
| Dividend | 0 |
| Forward Dividend | 9.04e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|